{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T08:20:46Z","timestamp":1780388446801,"version":"3.54.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1-3","license":[{"start":{"date-parts":[[1995,3,1]],"date-time":"1995-03-01T00:00:00Z","timestamp":794016000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genetica"],"published-print":{"date-parts":[[1995,3]]},"DOI":"10.1007\/bf01435003","type":"journal-article","created":{"date-parts":[[2005,4,12]],"date-time":"2005-04-12T10:40:02Z","timestamp":1113302402000},"page":"91-101","source":"Crossref","is-referenced-by-count":5,"title":["AZT toxicity and AIDS prophylaxis: Is AZT beneficial for HIV+ asymptomatic persons with 500 or more T4 cells per cubic millimeter?"],"prefix":"10.1007","volume":"95","author":[{"given":"Malcolm D.","family":"Zaretsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"CR1","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/0140-6736(93)93096-J","volume":"341","author":"J.-P. Aboulker","year":"1993","unstructured":"Aboulker, J.-P. & A.M. Swart, 1993. Preliminary analysis of the Concorde trial. Lancet 341:889?90.","journal-title":"Lancet"},{"key":"CR2","first-page":"949","volume":"6","author":"B. Abrams","year":"1993","unstructured":"Abrams, B., D. Duncan & I. Hertz-Piccolo, 1993. A prospective study of dietary intake and acquired immune deficiency syndrome in HIV-seropositive homosexual men. J.A.D.S. 6:949?958.","journal-title":"J.A.D.S."},{"key":"CR3","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJM199307293290510","volume":"329","author":"J.G. Bartlett","year":"1883","unstructured":"Bartlett, J.G., 1883. Zidovudine now or later? N. Engl. J. Med. 329:351?352.","journal-title":"N. Engl. J. Med."},{"key":"CR4","first-page":"334","volume":"35","author":"Centers for Disease Control","year":"1986","unstructured":"Centers for Disease Control, 1986. Classification system for human T-lymphotropic virus type III\/lymphadenopathy-associated virus infections. MMWR Morb. Mortal. Wkly., Rep. 35:334?339.","journal-title":"MMWR Morb. Mortal. Wkly., Rep."},{"key":"CR5","first-page":"1","volume":"36","author":"Centers for Disease Control","year":"1987","unstructured":"Centers for Disease Control, 1987. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR Morb. Mortal. Wkly. Rep. 36:1?15S.","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"CR6","doi-asserted-by":"crossref","first-page":"674","DOI":"10.7326\/0003-4819-118-9-199305010-00003","volume":"118","author":"S.S. Choi","year":"1993","unstructured":"Choi, S.S., W. Lagakos, R.T. Schooley & P.A. Volberding, 1993. CD4+ lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine. Ann. Intern. Med. 118:674?680.","journal-title":"Ann. Intern. Med."},{"key":"CR7","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJM198709033171011","volume":"317","author":"S.S. Cohen","year":"1987","unstructured":"Cohen, S.S., 1987. Anti-retroviral therapy for AIDS. N. Engl. J. Med. 317:629.","journal-title":"N. Engl. J. Med."},{"key":"CR8","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1056\/NEJM199307293290501","volume":"329","author":"D.A. Cooper","year":"1993","unstructured":"Cooper, D.A., J.M. Gatell, S. Kroon, N. Clumeck, J. Millard, F.-D. Goebel, J.N. Bruum, G. Stingl, R.L. Melville, J. Gonzalez-Lahoz, J.W. Stevens & A.P. Fiddian, 1993. Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. N. Engl. J. Med. 329:297?303.","journal-title":"N. Engl. J. Med."},{"key":"CR9","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"34","author":"D.R. Cox","year":"1972","unstructured":"Cox, D.R., 1972. Regression models and life-tables. J. Roy. Stat. Soc., Ser. B 34:187?202.","journal-title":"J. Roy. Stat. Soc., Ser. B"},{"key":"CR10","doi-asserted-by":"crossref","first-page":"530","DOI":"10.2307\/30166593","volume":"14","author":"G.L. Drusano","year":"1993","unstructured":"Drusano, G.L., 1993. Pharmacodynamics of antiretroviral chemotherapy. Infect. Control Hosp. Epidemiol. 14:530?6.","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"CR11","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1056\/NEJM198707233170401","volume":"317","author":"M.A. Fischl","year":"1987","unstructured":"Fischl, M.A., D.D. Richman, M.H. Grieco, M.S. Gottlieb, P.A. Volberding, O.L. Laskin, J.M. Leedom, J.E. Groopman, D. Moldvan, R.T. Schooley, G.G., Jackson, D.T. Durack & D. King, 1987. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebocontrolled trial. N. Engl. J. Med. 317:185?191.","journal-title":"N. Engl. J. Med."},{"key":"CR12","first-page":"321","volume":"17","author":"A. Ganser","year":"1989","unstructured":"Ganser, A., J. Greher, B. Volkers, S. Staszewski & D. Hoelzer, 1989. Inhibitory effect of azidothymidine, 2??3?-dideoxyadenosine, and 2??3?-dideoxycytdine on in vitro growth of hematopoietic progenitor cells from normal persons and from patients with AIDS. Exp. Hematol. 17:321?325.","journal-title":"Exp. Hematol."},{"key":"CR13","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/00002030-198909000-00001","volume":"3","author":"K. Gelmon","year":"1989","unstructured":"Gelmon, K., J.S.G. Montaner, M. Fanning, J.R.M. Smith, J. Falutz, C. Tsoukas, J. Gill, G. Wells, M. O'Shaughnessy, M. Wainberg & J. Ruedy, 1989. Nature, time course and dose dependence of zidovudine-related side effects: results from the Multicenter Canadian Azidothymidine Trial. Aids 3:555?561.","journal-title":"Aids"},{"key":"CR14","doi-asserted-by":"crossref","first-page":"502","DOI":"10.7326\/0003-4819-107-4-502","volume":"107","author":"P.S. Gill","year":"1987","unstructured":"Gill, P.S., M. Rarick, R.K. Brynes, D. Causey, C. Loureiro & A.M. Levine, 1987. Azidothymidine associated with bone marrow failure in the acquired immunodeficiency syndrome (AIDS). Ann. Intern. Med. 107:502?505.","journal-title":"Ann. Intern. Med."},{"key":"CR15","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/clpt.1990.131","volume":"48","author":"S.R. Gitterman","year":"1990","unstructured":"Gitterman, S.R., G.L. Drusano, M.J. Egorin & H.C. Standiford, 1990. Population pharmacokinetics of zidovudine. The Veterans Administration Cooperative Studies Group. Clin. Pharmacol. Ther. 48:161?167.","journal-title":"Clin. Pharmacol. Ther."},{"key":"CR16","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1365-2141.1988.tb02454.x","volume":"70","author":"M. Johnson","year":"1988","unstructured":"Johnson, M., T. Caiazzo J.-M. Molina, R. Donahue & J. Groopman, 1988. Inhibition of bone marrow myelopoiesis in vitro by antiretroviral nucleoside derivatives. Brit. J. Hematol. 70:137?141.","journal-title":"Brit. J. Hematol."},{"key":"CR17","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1073\/pnas.82.16.5535","volume":"82","author":"L.S. Kaminsky","year":"1985","unstructured":"Kaminsky, L.S., T. McHugh, D. Stites, P.A. Volberding, G. Henle, W. Henle & J.A. Levy, 1985. High prevalence of antibodies to acquired immune deficiency syndrome (AIDS)-associated retrovirus (ARV) in AIDS and related conditions but not in other disease states. Proc. Natl. Acad. Sci. U.S.A. 82:535?539.","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"CR18","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1001\/jama.1987.03390030056020","volume":"257","author":"W. Lang","year":"1987","unstructured":"Lang, W., R.E. Anderson, H. Perkins, D. Grant, R.M., Lyman, W. Winkelstein, Jr., R. Royce & J.A. Levy, 1987. Clinical, immunologic and serologic findings in men at risk for AIDS: The San Francisco Men's Health Study. JAMA 257:326?330.","journal-title":"JAMA"},{"key":"CR19","volume-title":"Statistical Methods for Survival Data Analysis","author":"E.T. Lee","year":"1980","unstructured":"Lee, E.T., 1980. Statistical Methods for Survival Data Analysis. Lifetime Learning Publications. Belmont, California."},{"key":"CR20","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1056\/NEJM199403173301102","volume":"330","author":"W.R. Lenderking","year":"1994","unstructured":"Lenderking, W.R., R.D. Gelber, D.J. Cotton, B.F. Cole, A. Goldhirsch, P.A. Volberding & M.A. Testa, 1994. Evaluation of the quality of life associated with zidovudine treatment in asymptomatic human immunodeficiency virus infection. N. Engl. J. Med. 330:738?743.","journal-title":"N. Engl. J. Med."},{"key":"CR21","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1126\/science.6206563","volume":"225","author":"J.A. Levy","year":"1984","unstructured":"Levy, J.A., A. Hoffman, S. Kramer, J.A. Landis, J.M., Shimabukuro & L.S. Oshiro, 1984. Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS. Science 225:840?842.","journal-title":"Science"},{"key":"CR22","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/0041-008X(89)90281-0","volume":"101","author":"M.I. Luster","year":"1989","unstructured":"Luster, M.I., D.R. Germolec K.L. White, Jr., B.A. Fuchs, M.M. Fort, J.E. Tomaszewski, M. Thompson, P.C. Blair, J.A. McCay, A.E. Munson & G.J. Rosenthal, 1989. A comparison of three nucleoside analogs with anti-retroviral activity on immune and hematopoietic functions in mice: In vitro toxicity to precursor cells and microstromal environment. Toxicol. Appl. Pharmacol. 101:328?339.","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"CR23","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S0140-6736(88)90262-0","volume":"ii","author":"N. Mir","year":"1988","unstructured":"Mir, N. & C. Costello, 1988. Zidovudine and bone marrow. Lancet ii:1195?1196.","journal-title":"Lancet"},{"key":"CR24","doi-asserted-by":"crossref","first-page":"7096","DOI":"10.1073\/pnas.82.20.7096","volume":"82","author":"H. Mitsuya","year":"1985","unstructured":"Mitsuya, H., K.J. Weinhold, P.A. Furman, M.H. St. Clair, S.N. Lehrman, R.C. Gallo, D. Bolognesi, D.W. Barry & S. Broder, 1985. 3?-Azidothymidine-3?-deoxythymidine (BW A509U): an antiviral agent that inhibits the injectivity and cytopathic effect of human T-lymphotropic virus type III\/lymphadenopathy-associated virus in vitro. Proc. Natl. Acad. Sci. USA 82:7096?7100.","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"CR25","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/hon.2900050204","volume":"5","author":"T.S. Namiki","year":"1987","unstructured":"Namiki, T.S., D.C. Boone & P.R. Meyer, 1987. A comparison of bone marrow findings in patients with acquired immunodeficiency syndrome (AIDS) and AIDS related conditions. Hematol. Oncol. 5:99?106.","journal-title":"Hematol. Oncol."},{"key":"CR26","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1001\/jama.1994.03510380039034","volume":"271","author":"D. Osmond","year":"1994","unstructured":"Osmond, D., E. charlebois, W. Lang, S. Shiboski & A. Moss, 1994. Changes in AIDS survival time in two San Francisco Cohorts of homosexual men, 1983 to 1993. JAMA 271:1083?1087.","journal-title":"JAMA"},{"key":"CR27","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/0140-6736(93)91109-Y","volume":"341","author":"R. Peto","year":"1993","unstructured":"Peto, R. & R. Collins, 1993. Immediate versus deferred Zidovudine. Lancet 341:1022?1023.","journal-title":"Lancet"},{"key":"CR28","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1056\/NEJM198810063191401","volume":"319","author":"P.A. Pizzo","year":"1988","unstructured":"Pizzo, P.A., J. Eddy, J. Falloon, F.M. Balis, R.F. Murphy, H., Moss, P. Wolters, P. Brouwers, P. Jarosinski & M. Rubin, 1988. Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection. N. Engl. J. Med. 319:889?896.","journal-title":"N. Engl. J. Med."},{"issue":"suppl 2A","key":"CR29","first-page":"208","volume":"85","author":"D.D. Richman","year":"1988","unstructured":"Richman, D.D. & J. Andrews, 1988. Results of continued monitoring of participants in the placebo-controlled trial of zidovudine for serious human immunodeficiency virus infection. Am. J. Med. 85 (suppl 2A):208?213.","journal-title":"Am. J. Med."},{"key":"CR30","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1056\/NEJM198707233170402","volume":"317","author":"D.D. Richman","year":"1987","unstructured":"Richman, D.D., M.A. Fischl, M.H. Grieco, M.S. Gottlieb, P.A. Volberding, O.L. Laskin, J.M. Leedom, J.E. Groopman, D. Moldvan, M.S. Hirsch, G.G. Jackson, D.T. Durack & S. Nusinoff-Lehrman, 1987. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N. Engl. J. Med. 317:192?197.","journal-title":"N. Engl. J. Med."},{"key":"CR31","first-page":"2583","volume":"270","author":"M.A. Sande","year":"1993","unstructured":"Sande, M.A., C.C. Carpenter, C.G. Cobbs, K.K. Holmes & J.P. Sanford, 1993. Antiretroviral therapy for adult HIV-infected patients. Recommendations from a state-of-the-art conference. National Institute of Allergy and Infectious Diseases JAMA 270:2583?2589.","journal-title":"National Institute of Allergy and Infectious Diseases JAMA"},{"key":"CR32","volume-title":"SAS, 6.04 edition","author":"SAS Institute","year":"1993","unstructured":"SAS Institute, 1993. SAS, 6.04 edition. Cary, N. Carolina: SAS Institute Inc."},{"key":"CR33","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1001\/jama.1994.03510290035033","volume":"271","author":"M. Schechter","year":"1994","unstructured":"Schechter, M., L.H. Harrison & N.A. Halsey, 1994. Coinfection with human T-cell lymphotropic virus type I and HIV in Brazil: impact on markers of HIV disease progression. JAMA 271:353?357.","journal-title":"JAMA"},{"key":"CR34","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0140-6736(94)90006-X","volume":"343","author":"M. Seligmann","year":"1994","unstructured":"Seligmann, M., D.A. Warrell, J.-P. Aboulker, C. Carbon, J.H. Darbyshire, J. Dormont, E. Eschwege, D.J. Girling, D.R. James, J.-P. Levy, T.E.A. Peto, D. Schwartz, A.B. Stone, I.V.D. Weller, R. Withnall, K. Gelmon, E. Lafon, A.M. Swart, V.R. Aber, A.G. Babiker, S. Lhoro, A.J. Nunn & M. Vray, 1994. Concorde: MRC\/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Lancet 343:871?881.","journal-title":"Lancet"},{"key":"CR35","volume-title":"Nonparametric Statistics","author":"S. Siegel","year":"1956","unstructured":"Siegel, S., 1956. Nonparametric Statistics, New York: McGraw-Hill."},{"issue":"Suppl 1","key":"CR36","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/clinids\/16.Supplement_1.S7","volume":"16","author":"J.P. Sommadossi","year":"1993","unstructured":"Sommadossi, J.P., 1993. Nucleoside analogs: Similarities and differences. Clin. Infect. Dis. 16 (Suppl 1):7?15S.","journal-title":"Clin. Infect. Dis."},{"key":"CR37","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1128\/AAC.31.3.452","volume":"31","author":"J.P. Sommadossi","year":"1989","unstructured":"Sommadossi, J.P. & R. Carlisle, 1989. Toxicity of 3?-azido-3?-deoxythymidine and 9-(1,3-dihydroxy-2-propoxymethyl)-guanine for normal human hematopoietic progenitor cells in vitro. Antimicrob. Agents Chemother. 31:452?454.","journal-title":"Antimicrob. Agents Chemother."},{"key":"CR38","first-page":"9","volume":"36","author":"J.P. Sommadossi","year":"1989","unstructured":"Sommadossi, J.P., R. Carlisle & Z. Zhou, 1989. Cellular pharmacology of 3?-azido-3?-deoxythymidine with evidence of incorporation into DNA of human bone marrow cells. Mol. Pharmacol. 36:9?14.","journal-title":"Mol. Pharmacol."},{"key":"CR39","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/0002-9343(84)90695-8","volume":"77","author":"J.L. Spivak","year":"1984","unstructured":"Spivak, J.L., B.S. Bender & T.C. Quinn, 1984. Hematologic abnormalities in the acquired immune deficiency syndrome. Am. J. Med. 77:224?228.","journal-title":"Am. J. Med."},{"key":"CR40","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/clpt.1992.79","volume":"51","author":"M.P. Stagg","year":"1992","unstructured":"Stagg, M.P., E.M. Cretton, L. Kidd, R.B. Diasio & J.P. Sommadossi, 1992. Clinical pharmacokinetics of 3?-azido-3?-deoxythymidine (zidovudine) and catabolites with formation of a toxic catabolite, 3?-amino-3?-deoxythymidine. Clin. Pharmacol. Ther. 51:668?676.","journal-title":"Clin. Pharmacol. Ther."},{"key":"CR41","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1172\/JCI113071","volume":"80","author":"C.C. Stella","year":"1987","unstructured":"Stella, C.C., A. Ganser & D. Hoelzer, 1987. Defective in vitro growth of the hemopoietic progenitor cells in the acquired immunodeficiency syndrome. J. Clin. Invest. 80:286?293.","journal-title":"J. Clin. Invest."},{"key":"CR42","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1056\/NEJM199004053221401","volume":"322","author":"P.A. Volberding","year":"1990","unstructured":"Volberding, P.A., S.W. Lagakos, M.A. Koch, C. Pettinelli, M.W. Myers, D.K. Booth, H.H. Balfour, Jr., R.C. Reichman, J.A. Bartlett, M.S. Hirsch, R.L. Murphy, W.D. Hardy, R. Soeiro, M.A. Fischl, J.G. Bartlet, T.C. Merigan, N.E. Hyslop, D.D. Richman, F.T. Valentine & L. Corey, 1990. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4+-positive cells per cubic millimeter. N. Engl. J. Med. 322:941?949.","journal-title":"N. Engl. J. Med."},{"key":"CR43","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.1987.03390030051019","volume":"257","author":"W. Winkelstein Jr.","year":"1987","unstructured":"Winkelstein, W. Jr., D.M. Lyman, N.P. Padian, R. Grant, M. Samuel, J.A. Wiley, R.E. Anderson, W. Lang, J. Riggs & J.A. Levy, 1987. Sexual practices and risk of infection by the human immunodeficiency virus, the San Francisco Men's Health Study. JAMA 257:321?325.","journal-title":"JAMA"},{"key":"CR44","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1056\/NEJM198702263160925","volume":"316","author":"R Yarchoan","year":"1987","unstructured":"Yarchoan, R & S. Broder, 1987. Development of antiretroviral therapy for the acquired immunodeficiency syndrome and related disorders. N. Engl. J. Med. 316:557?564.","journal-title":"N. Engl. J. Med."}],"container-title":["Genetica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF01435003.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF01435003\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF01435003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T15:12:19Z","timestamp":1735657939000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF01435003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,3]]},"references-count":44,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[1995,3]]}},"alternative-id":["BF01435003"],"URL":"https:\/\/doi.org\/10.1007\/bf01435003","relation":{},"ISSN":["0016-6707","1573-6857"],"issn-type":[{"value":"0016-6707","type":"print"},{"value":"1573-6857","type":"electronic"}],"subject":[],"published":{"date-parts":[[1995,3]]}}}